MoonLake Immunotherapeutics reported earnings of -$ 0.93 per MLTX share on Nov 4, 2026, beating analysts' expectations by
| Report Date | Nov 4, 2026 |
|---|---|
| Forecasted EPS | -$ 0.83 |
| Earnings Per Share (Surprise) | -$ 0.93 (-$ 0.10) |
| Last Year's EPS | -$ 0.88 |
| EPS YoY Change |
Out of the last 24 earnings reporting periods, MoonLake Immunotherapeutics beat analysts’ expectations 9 times and fell short of expectations 8 time(s). MoonLake Immunotherapeutics reported earnings per share of -$ 0.93 in the last report falling to reach an estimated EPS of -$ 0.83 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 4, 2026 | -$ 0.83 | -$ 0.93 | -$ 1.10 | |
| Aug 10, 2026 | -$ 0.91 | -$ 0.84 | -$ 0.87 | |
| May 11, 2026 | -$ 0.91 | -$ 0.98 | -$ 0.63 | |
| Feb 25, 2026 | -$ 0.92 | -$ 0.92 | -$ 0.72 | |
| Nov 5, 2025 | -$ 0.89 | -$ 1.10 | -$ 0.56 | |
| Aug 5, 2025 | -$ 0.73 | -$ 0.87 | -$ 0.39 | |
| May 12, 2025 | -$ 0.76 | -$ 0.63 | -$ 0.22 | |
| Feb 26, 2025 | -$ 0.53 | -$ 0.72 | -$ 0.12 | |
| Nov 7, 2024 | -$ 0.44 | -$ 0.56 | -$ 0.18 | |
| Aug 7, 2024 | -$ 0.28 | -$ 0.39 | -$ 0.23 | |
| May 7, 2024 | -$ 0.21 | -$ 0.22 | -$ 0.23 | |
| Feb 29, 2024 | -$ 0.21 | -$ 0.12 | -$ 0.31 | |
| Nov 14, 2023 | -$ 0.22 | -$ 0.18 | -$ 0.27 | |
| Aug 10, 2023 | -$ 0.25 | -$ 0.23 | -$ 0.34 | |
| May 12, 2023 | -$ 0.28 | -$ 0.23 | -$ 0.43 | |
| Mar 20, 2023 | -$ 0.32 | -$ 0.31 | -$ 0.15 | |
| Nov 14, 2022 | -$ 0.32 | -$ 0.27 | -$ 0.17 | |
| Aug 12, 2022 | -$ 0.54 | -$ 0.34 | -$ 0.89 | |
| May 16, 2022 | - | -$ 0.43 | -$ 0.01 | |
| Feb 17, 2022 | - | -$ 0.15 | -$ 0.01 |
MoonLake Immunotherapeutics’s stock was trading at $ 11.70 on Nov 3, 2026 a day before the last earnings report was released.Following the release of the earnings report, MLTX’s price decreased to $ 10.80 on Nov 5, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 4, 2026 | -$ 0.93 | $ 11.70 | $ 10.80 | |
| Aug 10, 2026 | -$ 0.84 | $ 18.26 | $ 16.59 | |
| May 11, 2026 | -$ 0.98 | $ 17.06 | $ 18.19 | |
| Feb 25, 2026 | -$ 0.92 | $ 18.20 | $ 17.68 | |
| Nov 5, 2025 | -$ 1.10 | $ 10.13 | $ 10.29 | |
| Aug 5, 2025 | -$ 0.87 | $ 53.32 | $ 52.76 | |
| May 12, 2025 | -$ 0.63 | $ 38.47 | $ 38.54 | |
| Feb 26, 2025 | -$ 0.72 | $ 40.73 | $ 41.77 | |
| Nov 7, 2024 | -$ 0.56 | $ 51.48 | $ 51.78 | |
| Aug 7, 2024 | -$ 0.39 | $ 43.93 | $ 46.05 | |
| May 7, 2024 | -$ 0.22 | $ 44.52 | $ 42.63 | |
| Feb 29, 2024 | -$ 0.12 | $ 56.81 | $ 50.92 | |
| Nov 14, 2023 | -$ 0.18 | $ 36.67 | $ 39.26 | |
| Aug 10, 2023 | -$ 0.23 | $ 54.23 | $ 56.14 | |
| May 12, 2023 | -$ 0.23 | $ 26.70 | $ 26.76 | |
| Mar 20, 2023 | -$ 0.31 | $ 23.14 | $ 22.01 | |
| Nov 14, 2022 | -$ 0.27 | $ 8.96 | $ 8.95 | |
| Aug 12, 2022 | -$ 0.34 | $ 5.79 | $ 7.13 | |
| May 16, 2022 | -$ 0.43 | $ 5.07 | $ 4.76 | |
| Feb 17, 2022 | -$ 0.15 | $ 9.95 | $ 9.94 |
MoonLake Immunotherapeutics released its most recent earnings reports in November 2026, August 2026, May 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
MoonLake Immunotherapeutics missed analysts’ expectations during the last earnings period by
